Takeda is the latest major pharmaceutical company to increase its investments in the U.S. market, partly in response to President Donald Trump’s tariff threats. The company’s CEO, Christophe Weber, announced on Thursday, during the company’s earnings call, that Takeda will be investing approximately $30 billion into its U.S. operations over the next five years.

“This reflects the fact that the U.S. is the world’s leading market for biopharmaceutical innovation, and I hope that will continue,” Weber remarked.

Other pharmaceutical companies that have announced plans to increase investments in the U.S. in anticipation of potential tariffs on the industry include Gilead, Roche, Novartis, and Johnson & Johnson.